Bibliography
- CREUTZFELDT HG: über eine eigenartige herdformige Erkrankung des Zentralnervensystems. Z. Neurol. Psychiatr. (1920) 57:1–18.
- JAKOB A: über eine eigenartige Erkrankung des Zen-tralnervensyste ms mit bemerkenswertem anatomis-chem Befunde (spastische pseudosklerotische Encephalomyelopathie mit disseminierten Degenera-tionsherden). Dtsch. Z Nervenheilk (1921) 70:132–146.
- PRUSINER SB: Novel proteinaceous infectious particles cause scrapie. Science (1982) 216:136–144.
- BOLTON DC, MCKINLEY MP, PRUSINER SB: Identification of a protein that purifies with the scrapie prion. Science (1982) 218:1309–1311.
- WILL RG, IRONSIDE JW, ZEIDLER M et al: A new variant of Creutzfeldt-Jakob disease in the UK. Lancet (1996) 347:921–925.
- CHAZOT G, BROUSSOLLE E, LAPRAS C et al: New variant of Creutzfeldt-Jakob disease in a 26-year-old French man. Lancet (1996) 347:1181.
- LASMEZAS CI, DESLYS JP, DEMAIMAY R eta].: BSE trans-mission to macaques. Nature (1996) 381:743–744.
- COLLINGE J, SIDLE KCL, MEADS J, IRONSIDE J, HILL AF: Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD. Nature (1996) 383:685–690.
- COUSENS SN, VYNNYCKY E, ZEIDLER M, WILL RG, SMITH PG: Predicting the CJD epidemic in humans. Nature (1997) 385:197–198.
- KIMBERLIN RH, WALKER CA: The antiviral compound HPA-23 can prevent scrapie when administered at the time of infection. Arch Virol (1983) 78:9–18.
- EHLERS B, DIRINGER H: Dextran sulphate 500 delays and prevents mouse scrapie by impairment of agent repli-cation in spleen. J. Gen. Vim]. (1984) 65:1325–1330.
- KIMBERLIN RH, WALKER CA: Suppression of scrapie infection in mice by heteropolyanion 23, dextran sul-fate, and some other polyanions. Antimicrob. Agents Chemother. (1986) 30:409–413.
- DIRINGER H, EHLERS B: Chemoprophylaxis of scrapie in mice. J. Gen. Vim]. (1991) 72:457–460.
- LADOGANA A, CASACCIA P, INGROSSO L eta].: Sulphate polyanions prolong the incubation period of scrapie-infected hamsters. J. Gen. Virol (1992) 73:661–665.
- CAUGHEY B, ERNST D, RACE R: Congo red inhibition of scrapie agent replication. J. Vim' (1993) 67:643–650.
- INGROSSO L, LADOGANA A, POCCHIARI M: Congo red prolongs the incubation period in scrapie-infected hamsters. J. Virol (1995) 69:506–508.
- AMYX H, SALAZAR AM, GAJDUSEK DC, GIBBS CJ: Chemotherapeutic trials in experimental slow virus disease. Neurology (1984) 34:149.
- POCCHIARI M, SCHMITTINGER S, LADOGANA A, MASULLO C.: Effects of Amphotericin B in intracerebrally scrapie inoculated hamster. In: Unconventional Virus Diseases of the Central Nervous System. Court IA, Dormont D, Brown P, Kingsbury DT (Eds.), CEA Diffusion, Paris (1986):314–323.
- POCCHIARI M, SCHMITTINGER S, MASULLO C: Am-photericin B delays the incubation period of scra pie in intracerebrally inoculated hamsters. J. Gen. Virol (1987) 68:219–223.
- POCCHIARI M, CASACCIA P. LADOGANA A: AmphotericinB: a novel class of antiscrapie drugs. J. Infect as. (1989) 160:795–802.
- DEMAIMAY R, ADJOU KT, LASMEZAS CI etaL: Pharmalogi-cal studies of a new derivative of amphotericin B, MS-8209, in mouse and hamster scrapie. J. Gen. Virol. (1994) 75:2499–2503.
- SAINT-JULIEN L, JOLY V, SEMAN M, CARBON C, YENI P: Activity of MS-8209, a nonester amphotericin B deriva-tive, in treatment of experimental systemic mycoses. Antimicrob. Ants Chem other. (1992) 36:2722–2728.
- PLESKOFF 0, SQL N, MARRAKCHI H eta].: Possible role of the V3 domain of gp120 in resistance to an Am-photericin B derivative (MS-8209) blocking human im-munodefiency virus entry. J. Virol. (1996) 70:8247–8251.
- MAGIEROWSKAJUNG M, CEFAI D, MARRAKCHI H eta].: In vitro determination of antiviral activity of MS-8209, a new amphotericin B derivative, against primary iso-lates of HIV-1. Res. Virol. (1996) 147:313–318.
- ADJOU KT, DEMAIMAY R, LASMEZAS C et al.: MS-8209, a new amphotericin B derivative, provides enhanced efficacy in delaying hamster scrapie. Antimicrob. Agents Chemother. (1995) 39:2810–2812.
- ADJOU KT, DEMAIMAY R, LASMEZAS CI etal: Differential effects of a new amphotericin B derivative, MS-8209, on mouse BSE and scrapie: implications for the mecha-nism of action of polyene antibiotics. Res. Virol (1996) 147:213–218.
- DEMAIMAY R, ADJOU KT, BERINGUE V et al.: Polyeneantibiotics in experimental transmissible spongiform encephalopathies. In: Transmissible Subacute Spongiform Encephalopathies: Prion Diseases. Court L, Dodet B (Eds.), Elsevier, Paris (1996):191–197.
- DORMONT D, YERAMIAN P, LAMBERT P eta]. In vitroandin vivo antiviral effects of HPA 23. In: Unconventional Virus Diseases of The Central Nervous System. Court LA, Dormont D, Brown P, Kingsbury DT (Eds.), CEA Diffusion, Paris (1980:324–337.
- MASULLO C, MACCHI G, XI YG: Pocchiari M: failure to ameliorate Creutzfeldt-Jakob disease with am-photericin B therapy. J. Infect. Dis. (1992) 165:784–785.
- HSICH G, KINNEY K, GIBBS CJ, LEEKH, HARRINGTON MG: The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopa-thies. New Engl. J. Med. (1996) 335:924–930.
- BROWN P: A therapeutic panorama of the spongiform encephalopathies. Antiviral Chem. Chemother. (1990) 1:75–83.
- ADJOU KT: Unpublished data.